Evaluation of molecular descriptors for antitumor drugs with respect to noncovalent binding to DNA and antiproliferative activity

BMC Pharmacology

Volumn 9, Issue , 2009, Pages 11-

  Portugal, José ^a  

^a INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHARTREUSIN; CHROMOMYCIN; CONGOCIDINE; DACTINOMYCIN; DAUNORUBICIN; DISTAMYCIN A; DNA; DOXORUBICIN; ECHINOMYCIN; ELSAMICIN A; EPIRUBICIN; ETHIDIUM; MITHRAMYCIN A; MITOXANTRONE; UNCLASSIFIED DRUG; INTERCALATING AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COMPUTER MODEL; CYTOTOXICITY; DRUG DNA BINDING; HUMAN; HUMAN CELL; INTERCALATION COMPLEX; PREDICTION; ANIMAL; CHEMISTRY; CLASSIFICATION; CLUSTER ANALYSIS; DRUG EFFECT; DRUG SCREENING; FACTUAL DATABASE; MATHEMATICAL COMPUTING; METABOLISM; METHODOLOGY; NATIONAL HEALTH ORGANIZATION; PRINCIPAL COMPONENT ANALYSIS; REGRESSION ANALYSIS; STATISTICAL MODEL; UNITED STATES;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CLUSTER ANALYSIS; DATABASES, FACTUAL; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; INTERCALATING AGENTS; MODELS, STATISTICAL; NATIONAL CANCER INSTITUTE (U.S.); NUMERICAL ANALYSIS, COMPUTER-ASSISTED; PRINCIPAL COMPONENT ANALYSIS; REGRESSION ANALYSIS; UNITED STATES;

EID: 70350727269     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-9-11     Document Type: Article

References (42)

1. Hurley LH. DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2002, 2:188-200. 10.1038/nrc749, 11990855.
2. Weinstein JN, Myers TG, O' Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL. An information-intensive approach to the molecular pharmacology of cancer. Science 1997, 275:343-349. 10.1126/science.275.5298.343, 8994024.
3. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56:185-229. 10.1124/pr.56.2.6, 15169927.
4. Strekowski L, Wilson B. Noncovalent interactions with DNA: an overview. Mutat Res 2007, 623:3-13.
5. Chaires JB. A thermodynamic signature for drug-DNA binding mode. Arch Biochem Biophys 2006, 453:26-31. 10.1016/j.abb.2006.03.027, 16730635.
6. Wheate NJ, Brodie CR, Collins JG, Kemp S, Aldrich-Wright JR. DNA intercalators in cancer therapy: organic and inorganic drugs and their spectroscopic tools of analysis. Mini Rev Med Chem 2007, 7:627-648. 10.2174/138955707780859413, 17584161.
7. Garbett NC, Chaires JB. Binding: a polemic and rough guide. Methods Cell Biol 2008, 84:3-23.
8. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000, 24:236-244. 10.1038/73439, 10700175.
9. Huang R, Wallqvist A, Covell DG. Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action. J Med Chem 2006, 49:1964-1979. 10.1021/jm051029m, 16539384.
10. Covell DG, Huang R, Wallqvist A. Anticancer medicines in development: assessment of bioactivity profiles within the National Cancer Institute anticancer screening data. Mol Cancer Ther 2007, 6:2261-2270. 10.1158/1535-7163.MCT-06-0787, 17699723.
11. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, Grimshaw A, Theodorescu D. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA 2007, 104:13086-13091. 10.1073/pnas.0610292104, 1941805, 17666531.
12. Baguley BC, Marshall ES. In vitro modelling of human tumour behaviour in drug discovery programmes. Eur J Cancer 2004, 40:794-801. 10.1016/j.ejca.2003.12.019, 15120035.
13. Mansilla S, Piña B, Portugal J. Daunorubicin-induced variations in gene transcription: commitment to proliferation arrest, senescence and apoptosis. Biochem J 2003, 372:703-711. 10.1042/BJ20021950, 1223450, 12656675.
14. Huang R, Wallqvist A, Thanki N, Covell DG. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action. Pharmacogenomics J 2005, 5:381-399. 10.1038/sj.tpj.6500331, 16103895.
15. Ring BZ, Chang S, Ring LW, Seitz RS, Ross DT. Gene expression patterns within cell lines are predictive of chemosensitivity. BMC Genomics 2008, 9:74. 10.1186/1471-2164-9-74, 2263043, 18261237.
16. Priebe W, Fokt I, Przewloka T, Chaires JB, Portugal J, Trent JO. Exploting anthracycline scaffold for designing DNA-targeting agents. Methods Enzymol 2001, 340:529-555. full_text, 11494869.
17. Portugal J, Cashman DJ, Trent JO, Ferrer-Miralles N, Przewloka T, Fokt I, Priebe W, Chaires JB. A new bisintercalating anthracycline with picomolar DNA binding affinity. J Med Chem 2005, 48:8209-8219. 10.1021/jm050902g, 2522373, 16366602.
18. Denny WA, Atwell GJ, Baguley BC. Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity. J Med Chem 1983, 26:1625-1630. 10.1021/jm00365a014, 6688830.
19. Shapiro SS, Wilk MB. An analysis of variance test for normality. Biometrika 1965, 52:591-599.
20. Pedhazur EJ. Multiple Regression in Behavioral Research 1997, Orlando, FL: Harcourt Brace, 3.
21. Byrn SR, Dolch GD. Analysis of binding of daunorubicin and doxorubicin to DNA using computerized curve-fitting procedures. J Pharm Sci 1978, 67:688-693. 10.1002/jps.2600670532, 641812.
22. Lown JW, Morgan AR, Yen SF, Wang YH, Wilson WD. Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. Biochemistry 1985, 24:4028-4035. 10.1021/bi00336a034, 4052381.
23. Kuwahara J, Sugiura Y. Sequence-specific recognition and cleavage of DNA by metallobleomycin: minor groove binding and possible interaction mode. Proc Natl Acad Sci USA 1988, 85:2459-2463. 10.1073/pnas.85.8.2459, 280016, 2451823.
24. Wadkins RM, Graves DE. Thermodynamics of the interactions of m-AMSA and o-AMSA with nucleic acids: influence of ionic strength and DNA base composition. Nucleic Acids Res 1989, 17:9933-9946. 10.1093/nar/17.23.9933, 335223, 2602146.
25. Aich P, Sen R, Dasgupta D. Role of magnesium ion in the interaction between chromomycin A3 and DNA: binding of chromomycin A3-Mg2+ complexes with DNA. Biochemistry 1992, 31:2988-2997. 10.1021/bi00126a021, 1550824.
26. Barceló F, Capó D, Portugal J. Thermodynamic characterization of the multivalent binding of chartreusin to DNA. Nucleic Acids Res 2002, 30:4567-4573. 10.1093/nar/gkf558, 137122, 12384604.
27. Lin LP, Huang LS, Lin CW, Lee CK, Chen JL, Hsu SM, Lin S. Determination of binding constant of DNA-binding drug to target DNA by surface plasmon resonance biosensor technology. Curr Drug Targets Immune Endocr Metabol Disord 2005, 5:61-72. 10.2174/1568008053174697, 15777205.
28. Leng F, Chaires JB, Waring MJ. Energetics of echinomycin binding to DNA. Nucleic Acids Res 2003, 31:6191-6197. 10.1093/nar/gkg826, 275468, 14576305.
29. Barceló F, Scotta C, Ortiz-Lombardía M, Méndez C, Salas JA, Portugal J. Entropically-driven binding of mithramycin in the minor groove of C/G-rich DNA sequences. Nucleic Acids Res 2007, 35:2215-2226. 10.1093/nar/gkm037, 1874653, 17369273.
30. Ren J, Jenkins TC, Chaires JB. Energetics of DNA intercalation reactions. Biochemistry 2000, 39:8439-8447. 10.1021/bi000474a, 10913249.
31. Haq I. Thermodynamics of drug-DNA interactions. Arch Biochem Biophys 2002, 403:1-15. 10.1016/S0003-9861(02)00202-3, 12061796.
32. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001, 46:3-26. 10.1016/S0169-409X(00)00129-0, 11259830.
33. Prabhakar YS, Handa A, Gupta SP. Quantitative correlations of biological activities of dactinomycin analogs and methotrexate derivatives with van der Waals volume. Arzneimittelforschung 1985, 35:1030-1033.
34. Mansilla S, Portugal J. Sp1 transcription factor as a target for anthracyclines: Effects on gene transcription. Biochimie 2008, 90:976-987. 10.1016/j.biochi.2007.12.008, 18226599.
35. Gniazdowski M, Denny WA, Nelson SM, Czyz M. Effects of anticancer drugs on transcription factor-DNA interactions. Expert Opin Ther Targets 2005, 9:471-489. 10.1517/14728222.9.3.471, 15948668.
36. Finlay GJ, Atwell GJ, Baguley BC. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions. Oncol Res 1999, 11:249-254.
37. Chilin A, Marzaro G, Marzano C, Dalla Via L, Ferlin MG, Pastorini G, Guiotto A. Synthesis and antitumor activity of novel amsacrine analogs: the critical role of the acridine moiety in determining their biological activity. Bioorg Med Chem 2009, 17:523-529. 10.1016/j.bmc.2008.11.072, 19101158.
38. Rojas M, Casado M, Portugal J, Piña B. Selective inhibition of yeast regulons by daunorubicin: a transcriptome-wide analysis. BMC Genomics 2008, 9:358. 10.1186/1471-2164-9-358, 2536678, 18667070.
39. Zhang MQ, Wilkinson B. Drug discovery beyond the 'rule-of-five'. Curr Opin Biotechnol 2007, 18:478-488. 10.1016/j.copbio.2007.10.005, 18035532.
40. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y, Yamori T. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 2002, 62:1139-1147.
41. Hendry LB, Mahesh VB, Bransome ED, Ewing DE. Small molecule intercalation with double stranded DNA: implications for normal gene regulation and for predicting the biological efficacy and genotoxicity of drugs and other chemicals. Mutat Res 2007, 623:53-71.
42. Wang H, Klinginsmith J, Dong X, Lee AC, Guha R, Wu Y, Crippen GM, Wild DJ. Chemical data mining of the NCI human tumor cell line database. J Chem Inf Model 2007, 47:2063-2076. 10.1021/ci700141x, 17915856.